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Lipopolysaccharide (LPS) is a bacterial wall endotoxin producing many pathophysiological
conditions including myocardial inﬂammation leading to cardiotoxicity. Epoxyeicosatrienoic
acids (EETs) are biologically active metabolites of arachidonic acids capable of activating
protective cellular pathways in response to stress stimuli. EETs evoke a plethora of
pathways limiting impairments of cellular structures, reducing cell death, and promoting
anti-inﬂammatory reactions in various cell types. Considering EETs are capable of producing
various biological protective effects, we hypothesized that EETs would protect rat neonatal
cardiomyocytes (NCM) against LPS-induced cytotoxicity. In this study, we used a dual-
acting, synthetic analog of EETs, UA-8 [13-(3-propylureido)tridec-8-enoic acid], possessing
both EET-mimetic and soluble epoxide hydrolase selective inhibitory properties and 14,15-
EET as a model of canonical EET molecules. We found that both UA-8 and 14,15-EET
signiﬁcantly improved cell viability and mitochondrial function of cardiomyocytes exposed
to LPS. Furthermore, treatment with UA-8 or 14,15-EET resulted in signiﬁcant attenuation
of LPS-triggered pro-inﬂammatory response, caspase-3 activation and reduction in the
total antioxidant capacity in cardiomyocytes. Importantly, EET-mediated effects were
signiﬁcantly reduced by pharmacological inhibition of peroxisome proliferator-activated
receptors γ (PPARγ) suggesting that PPARγ signaling was required for EETs exerted
protective effects. Data presented in the current study demonstrate that activation of
PPARγ signaling plays a crucial role in EET-mediated protection against LPS-cytotoxicity
in cardiomyocytes.
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INTRODUCTION
Inﬂammation is a complex and highly orchestrated process
involved in protecting cells from injury; yet, mounting evidence
suggests that overactivated inﬂammatory responses contribute to
the initiation and development of a wide range of diseases includ-
ing cardiovascular diseases (CVDs) (Gabay and Kushner, 1999;
Ridker and Silvertown, 2008). Bacterial endotoxin lipopolysac-
charide (LPS) is considered one of the major causes in initiating
low-grade systemic inﬂammation associatedwith cardiac dysfunc-
tion (Niebauer et al., 1999; Opal et al., 1999). Binding of LPS to
TLR-4 receptors results in execution of the IKK-NF-kB inﬂam-
matory program (Akira et al., 2001) leading to the release of
pro-inﬂammatory cytokines such as TNFα, IL-6, IL-1, andMCP-1
(Ohlsson et al., 1990; Carlson et al., 2005; Fallach et al., 2010). The
LPS-triggered release of pro-inﬂammatory cytokines can directly
cause cardiac damage via numerous mechanisms including acti-
vation of JNK signaling (Hambleton et al., 1996; Charalambous
et al., 2007; Drosatos et al., 2011), increased oxidative stress (Ben-
Shaul et al., 2001), decreased β-adrenergic activity (Yasuda and
Lew, 1997), reduced peroxisome proliferator-activated receptors
(PPARs) expression and DNA binding activity (Feingold et al.,
2004; Maitra et al., 2009; Samokhvalov et al., 2012) or direct mito-
chondrial damage (Choumar et al., 2011). Although LPS triggered
responses are well documented, the precise cellular and molecular
mechanism(s) involved in LPS-induced myocardial dysfunction
remains very poorly delineated.
Arachidonic acid is a 20-carbon polyunsaturated fatty acid
found in cell membranes. Activation of phospholipase A2 results
in the release of arachidonic acid, which can undergo enzymatic
conversion forming biologically active lipid molecules (Rosenthal
et al., 1995; Roman, 2002; Levick et al., 2007). Cytochrome P450
(CYP) epoxygenases are known to metabolize arachidonic acid
into four regioisomeric epoxide metabolites, epoxyeicosatrienoic
acids (EETs): 5,6-, 8,9-, 11,12-, and 14,15-EET (Fang et al.,
2001; Kim et al., 2004). Reported EET-mediated effects include
enhanced autophagy (Samokhvalov et al., 2013), inhibition of
apoptosis (Dhanasekaran et al., 2008), mitochondrial protection
(Katragadda et al., 2009) and cell proliferation (Imig, 2012).
Numerous in vitro and in vivo studies provide strong evidence that
EETs have anti-inﬂammatory properties (Node et al., 1999; Deng
et al., 2010; Imig, 2012), which involves inhibition of the IKK-
NF-kB cascade (Rompe et al., 2010). For example, 11,12-EET was
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found to prevent LPS-triggered activation of the inﬂammatory
response in monocytes by suppressing NF-kB signaling (Kozak
et al., 2003). However, the exact role EETs have in regulating
anti-inﬂammatory reactions in cardiac cells remains unknown.
Preventing a pathological activation of the inﬂammatory
response requires a tight coordination of biological processes
directed to effectively suppress the pro-inﬂammatory response
while promoting anti-inﬂammatory reactions (Chinetti et al.,
2001; Jones et al., 2002; Liu et al., 2005; Moraes et al., 2006).
PPARs are ligand-activated transcription factors and members of
the nuclear hormone receptor superfamily (Wray and Bishop-
Bailey, 2008). PPAR nuclear receptors sense various biological
molecules and regulate many cellular functions such as fatty acid
metabolism and lipid transport (Desvergne and Wahli, 1999),
inﬂammatory responses (Wang et al., 2002; Moraes et al., 2006),
cell differentiation (Barak et al., 1999) and tissue development
(Rosen et al., 1999). There are three PPAR isoforms character-
ized (α, γ, and β/δ) that regulate physiologically distinct processes
(Delerive et al., 2001; Bocher et al., 2002). Importantly, activa-
tion of PPARs, particularly PPARγ, suppresses NF-kB-induced
expression of inﬂammatory cytokines (Liu et al., 2005; Wang
et al., 2010). Interestingly, EETs have been identiﬁed as potent
PPARs activators (Node et al., 1999; Liu et al., 2005; Ng et al.,
2007), suggesting that anti-inﬂammatory effects of EETs might be
mediated via PPAR-signaling. Despite already published studies,
the existing knowledge regarding the mechanisms through which
EETs attenuate LPS-induced cytotoxicity appears to be insufﬁ-
cient. Considering LPS down-regulates PPAR-mediated signaling,
thus initiating the pro-inﬂammatory response, our objective was
to determine if the anti-inﬂammatory effects of EETs required
activation of PPARγ signaling in neonatal cardiomyocytes
(NCMs).
MATERIALS AND METHODS
CELL CULTURE
Neonatal cardiomyocytes were isolated from 3 day-old pups as
described before (Samokhvalov et al., 2012). Each isolation was
done on a different day to perform a separate set of experiments
(N = 3–4). Isolated NCMs were cultivated in DMEM medium
supplemented with 10% FBS at 37◦C in a humidiﬁed incuba-
tor maintaining 5% CO2 and 95% air. Cell viability was assessed
using a Trypan Blue exclusion assay as previously described
(Samokhvalov et al., 2013). Beating rate of cardiomyocytes was
evaluated by counting the number of beats permin in ﬁve different
cell clusters in ﬁve independently blinded experiments.
TREATMENT PROTOCOLS
In this study, NCMswere treated with LPS (1μg/ml), a novel EET-
analog, UA-8 [13-(3-propylureido)tridec-8-enoic acid (1 μM)],
that possesses EET-mimetic and soluble epoxide hydrolase (sEH)
inhibitory properties, and/or 14,15-EET (1 μM) as a model EETs
(Batchu et al., 2011). The chemical structure and properties of the
UA-8 were previously described and depicted in Figure 1A; UA-8
can inhibit sEH at nanomolar concentrations (IC50 46 nM; Batchu
et al., 2011). In order to block EET-mediated effects, we utilized
the antagonist, 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE,
10 μM). PPARγ was inhibited with a speciﬁc pharmacological
agent GW9662 (1 μM; Seargent et al., 2004). Stock solutions of
UA-8 and GW9662 were prepared in DMSOwhile 14,15-EET, and
14,15-EEZE were prepared in 100% ethanol, ﬁnal concentrations
of both solvents were less than 0.01% of the treatment solutions.
METABOLIC ASSESSMENTS
In order to test overall efﬁciency of mitochondrial oxidative
metabolism, we used a kit (Sigma–Aldrich, Co., Oakville, ON,
CAN)measuring ADP/ATP ratio in cell lysates by luciferase-based
method. The intensity of emitted light occurred during the ﬁrst
reaction is proportional to the level of ADP in the sample while
the intensity of the second reaction reﬂects the level of ATP. Alter-
natively, MTT assay was employed to examine total oxidative
metabolism as previously described (Samokhvalov et al., 2013).
The intensity of reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide to formazan crystals by mitochon-
drial dehydrogenases positively correlates with the overall activity
of oxidative metabolism (Wang et al., 2010). Optical density of
DMSO extracted formazan was measured spectrophotometrically
at 595 nm.
TOTAL ANTIOXIDANT CAPACITY, CASPASE-3, AND 20S PROTEASOME
ACTIVITY ASSAYS
We determined the total antioxidant activity to provide an indi-
cation of the relative ROS status. Brieﬂy, the principle of the
antioxidant assay is formation of a ferryl myoglobin radical from
metmyoglobin and hydrogen peroxide, which oxidizes the ABTS
[2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) produc-
ing a radical cation, ABTS+, a soluble chromogen that is green in
color and can be determined spectrophotometrically at 405 nm.
(Sigma–Aldrich, Co, Oakville, ON, USA). To assess activation
of apoptosis, we measured caspase-3 activity by employing a
spectroﬂuorimetric assay, which detects AMC ﬂuorescence after
cleavage of AC-DEVD-AMC substrate as described previously
(Seubert et al., 2002). Total proteasome activity as a marker of
unspeciﬁc degenerative processes (Samokhvalov et al., 2013) was
determined in the whole cell lysates based on monitoring the
release of AMC by proteolytic cleavage of the peptide Suc-LLVY-
AMC (CHEMICON Inc, Billerica,MA,USA) by 20S proteasomes.
Fluorescence was monitored in both caspase-3 and total protea-
some assays at wavelengths of 380 nm (excitation) and 460 nm
(emission). Speciﬁc activities were determined from a standard
curve established with AMC.
CYTOKINES ASSAY
Medium was centrifuged (5 min at 5000 g) supernatants were
analyzedbyELISA for ratTNFα andMCP-1 (ABCAM,Cambridge,
UK).
NF-kB AND PPARγ DNA BINDING ASSAYS
NF-kB DNA binding assay was measured using an ELISA kit from
Active Motif (Carlsbad, CA, USA). PPARγ DNA biding activity
wasmeasured using an ELISA kit fromABCAM(Cambridge,UK).
Brieﬂy, the assays are based on the speciﬁc recognition of PPARγ
or NF-kB response elements by intracellular PPARγ or NF-kB
transcription factors contained in cell lysates.
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FIGURE 1 |Treatment with UA-8 attenuates LPS-induced decrease in
cell viability, oxidative metabolic activity and improves contractility
of neonatal cardiomyocytes. NCMs were treated with LPS (1μg/ml)
and/or UA-8 (1 μm) in the presence or absence of 14,15-EEZE (10 μm)
for 24 h. (A) Chemical structures of 14,15-EET, UA-8, 14,15-EEZE.
(B) UA-8 improved LPS-lowered cell viability. (C) Mitochondrial oxidative
metabolic activity was preserved by treatment with UA-8. (D) UA-8
prevented LPS-induced increase in ADP/ATP ratio. (E) UA-8 attenuated
LPS-impaired contractility of NCMs. Values are represented as
mean ± SEM, N = 3–4. Signiﬁcance was set at P < 0.05.
* Signiﬁcantly different from control. # Signiﬁcantly different from
LPS-treated cells.
STATISTICAL ANALYSIS
Data are presented as mean ± SEM. Statistical analysis was based
on one-way ANOVA with a Bonferonni post hoc test; P < 0.05 was
considered statistically signiﬁcant.
RESULTS
TREATMENT WITH UA-8 ATTENUATED LPS-INDUCED DECREASE IN
CELL VIABILITY AND FUNCTIONAL ACTIVITY
Lipopolysaccharide is a well-known cytotoxic agent promoting
rapid cell death (Charalambous et al., 2007). After 24 h, more
than 50% of NCMs exposed to LPS were dead as evaluated by
a Trypan blue exclusion assay (Figure 1B). Addition of UA-8
dramatically prevented LPS-triggered decrease in cell viability.
However, co-treatmentwith 14,15-EEZE, an EET antagonist, abol-
ishedUA-8 protection against LPS (Figure 1B). In order to further
examine protective effect of UA-8, we examined total oxidative
metabolism in cardiomyocytes exposed to LPS by MTT assay.
Figure 1C demonstrates that treatment with LPS for 24 h caused
a signiﬁcant decline in oxidative metabolic activity suggesting that
mitochondrial function was severely compromised. Treatment
with UA-8 ameliorated LPS-induced exacerbation in mitochon-
drial function, which was in turn abolished by a co-treatment
with 14,15-EEZE. Paralleling our observations with regard to
impairments in mitochondrial function, LPS also caused a robust
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increase in ADP/ATP ratio that was greatly reversed by addition of
UA-8 (Figure 1D), suggesting mitochondria in LPS treated NCMs
could no longer meet cellular demands for ATP. The ability of car-
diomyocytes to contract in vitro reﬂects their functional activity
and requires a continuous supply of ATP to sustain normal con-
tractility (Yasuda and Lew, 1997). We found that treatment with
LPS for 24 h induced a dramatic reduction in contractile activ-
ity of NCMs indicative of severe impairments in their functional
activity (Figure 1E). Treatment with UA-8 prevented the loss of
contractile activity inNCMs,whichwas abolished by co-treatment
with 14,15-EEZE. These data demonstrate that the LPS triggered
mitochondrial dysfunction in NCMs led to ATP deprivation asso-
ciated with decreased contractility and resulting in cell death, was
rescued by treatment with UA-8.
LPS-INDUCED ACTIVATION OF INFLAMMATORY RESPONSE IS
ATTENUATED BY UA-8
Lipopolysaccharide-induced cytotoxicity is largely mediated
through robust activation of the pro-inﬂammatory response
(Charalambous et al., 2007). Therefore, it was important to
investigate if inﬂammatory markers were up-regulated in our
experimental model of LPS-induced cytotoxicity and whether
treatment with UA-8 could reduce them. Accordingly, we ﬁrst
assessed NF-kB DNA binding activity, a test revealing functional
activity of the major factor orchestrating the pro-inﬂammatory
response. Figure 2A illustrates that treatment with LPS for 24 h
induced a pronounced increase in NF-kB DNA binding activ-
ity. Furthermore, we also demonstrate that LPS promoted a
strong release of the major pro-inﬂammatory cytokines TNFα
and MCP-1 from cardiomyocytes (Figures 2B,C). These changes
in the levels of the inﬂammatory markers indicate a pro-
found activation of the pro-inﬂammatory response caused by
LPS. Co-treatment of cells with UA-8 signiﬁcantly attenuated
the LPS-triggered inﬂammatory response in cardiomyocytes as
seen with reduced NF-kB DNA binding activity and decreased
release of TNFα and MCP-1 cytokines. Co-treatment with 14,15-
EEZE abolished the anti-inﬂammatory effects of UA-8, thus
suggesting the UA-8 associated improvements in LPS-triggered
inﬂammatory response were realized through EET-speciﬁc
pathways.
UA-8 AMELIORATES CELLULAR STRESS REACTIONS IN RESPONSE
TO LPS
Oxidative stress has been recognized as a major unspeciﬁc stress
reaction mediating LPS cytotoxicity (Ben-Shaul et al., 2001). In
order to examine the involvement of oxidative stress in LPS-
induced cytotoxicity, we employed a test measuring a total pool of
enzymatic and non-enzymatic components of the cellular antiox-
idant defense, thereby revealing cell ability to withstand oxidative
stress. We found that LPS caused a collapse in total antioxidant
capacity of cardiomyocytes indicative of activated oxidative stress.
However, treatment with UA-8 signiﬁcantly preserved the total
antioxidant capacity of LPS-exposed cardiomyocytes, thus, pro-
viding a piece of evidence that activation of oxidative stress did
not occur in full (Figure 3A). The accumulation of ubiquinated
proteins triggers 20S proteasome activity to remove the targeted
damaged proteins. As such, 20S proteasome activity can be uti-
lized as a marker of unspeciﬁc cellular degenerative processes
(Samokhvalov et al., 2013). Interestingly, treatmentwith LPS failed
to induce any alterations in 20S proteasome activity (Figure 3B).
LPS triggers a number of complex degenerative reactions culmi-
nating in cell death, often through apoptosis (Turdi et al., 2012).
Consistent with these reports, Figure 3C demonstrates that treat-
ment with LPS provoked a robust activation of caspase-3, which
indicates initiation of apoptosis. Treatment with UA-8 dramati-
cally decreased LPS-induced activation of caspase-3. Importantly,
all observed effects of UA-8 were abolished by a co-treatment
with 14,15-EEZE providing further support for the involvement
of speciﬁc EET’s signaling.
PPARγ INHIBITION PREVENTS UA-8-ASSOCIATED PROTECTIVE
EFFECTS IN LPS-INDUCED CYTOTOXICITY
Peroxisome proliferator-activated receptors nuclear receptors are
broadly recognized as signaling factors, which are involved in
regulating inﬂammatory responses. Activation of PPARs can
both stimulate an anti-inﬂammatory response and suppress the
FIGURE 2 | UA-8 inhibited inflammatory response triggered by LPS in
NCMs. NCMs were treated with LPS (1 μg/ml) and/or UA-8 (1 μm) in
the presence or absence of 14,15-EEZE (10 μm) for 24 h. (A) UA-8
suppressed LPS-triggered up-regulation of NF-kB DNA binding activity in
NCMs. (B) and (C) UA-8 robustly diminished the release of TNFα and
MCP-1 from NCMs exposed to LPS. Values are represented as
mean ± SEM, N = 3–4. Signiﬁcance was set at P < 0.05. * Signiﬁcantly
different from control. # Signiﬁcantly different from LPS-treated cells.
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FIGURE 3 |Treatment with UA-8 reduced LPS-evoked activation of
cellular stress responses. NCMs were treated with LPS (1 μg/ml)
and/or UA-8 (1 μm) in the presence or absence of 14,15-EEZE (10 μm)
for 24 h. (A) UA-8 sustained the total antioxidant capacity of NCMs
exposed to LPS. (B) No changes were observed in 20S total
proteasome activity after treatment either with UA-8 or with LPS.
(C) UA-8 prevented LPS-induced activation of caspase-3. Values are
represented as mean ± SEM, N = 3–4. Signiﬁcance was set at
P < 0.05. * Signiﬁcantly different from control. # Signiﬁcantly different
from LPS-treated cells.
pro-inﬂammatory response. While EETs activate PPARs through
ligand-speciﬁc interaction (Liu et al., 2005; Ng et al., 2007), LPS
causes a reduction in the expression of PPARs (Feingold et al.,
2004; Maitra et al., 2009). Thus, we explored whether UA-8 asso-
ciated protective effects occurred through PPAR-signaling. First,
we assessed if treatments with UA-8 and/or LPS could affect
PPARγ DNA binding activity. We found that treatment with
LPS caused a dramatic reduction in PPARγ DNA binding activ-
ity. In contrast, treatment with UA-8 strongly enhanced PPARγ
DNA binding activity. Furthermore, treatment with UA-8 also
signiﬁcantly restored LPS-induced drop in PPARγ DNA binding
activity (Figure 4). In order to examine the role of PPARγ, we
treated cardiomyocytes with GW 9662, a speciﬁc pharmacologi-
cal inhibitor of PPARγ signaling. Pharmacological inhibition of
PPARγ with GW 9662 (1 μM) was conﬁrmed by assessing DNA
binding activity, which showed strongly reduced PPARγ DNA
binding in all experimental groups (Figure 4). Pharmacological
inhibition of PPARγ prevented UA-8-associated protective effects.
Our data demonstrate that treatment with GW 9662 blocked
UA-8 improved cell viability (Figure 5A) and ADP/ATP ratio
(Figure 5B) in LPS-treated NCMs. Furthermore, pharmacolog-
ical inhibition of PPARγ with GW 9662 prevented UA-8-evoked
anti-inﬂammatory and anti-apoptotic effects as observedwithNF-
kB DNA binding (Figure 5C) and caspase-3 activities (Figure 5D)
in NCMs exposed to LPS. These results provide evidence that
UA-8-associated protective effects require activation of PPARγ
signaling.
14,15-EET RECAPITULATES PROTECTIVE EFFECTS ASSOCIATED
WITH UA-8
UA-8 represents a synthetic compound with structural similari-
ties to EETs and sEH inhibitor properties (Batchu et al., 2011).
Thus, in order to further determine if the effects were mediated by
EET-mediated events, we utilized 14,15-EET as a model to explore
similarities observed with UA-8. NCMs treated with 14,15-EET
(1 μM) demonstrated signiﬁcantly better cell viability following
FIGURE 4 | Effect of UA-8 and LPS treatments on PPARγ DNA binding
activity in NCMS and its pharmacological inhibition with GW 9662.
NCMs were treated with LPS (1 μg/ml) and/or UA-8 (1 μm) in the presence
or absence of 14,15-EEZE (10 μm) for 24 h. GW 9662 (1 μm), a
pharmacological inhibitor of PPARγ, was added when indicated. Values are
represented as mean ± SEM, N = 3–4. Signiﬁcance was set at P < 0.05.
* Signiﬁcantly different from control. # Signiﬁcantly different from
LPS-treated cells.
LPS treatment (Figure 6A). Furthermore, treatment with 14,15-
EET signiﬁcantly reduced LPS-triggered NF-kB DNA binding
activity and release of TNFα (Figures 6B,C). These observations
illustrate that treatment with 14,15-EET effectively suppressed
LPS-induced pro-inﬂammatory responses inNCMs. Finally, treat-
ment with 14,15-EET signiﬁcantly enhanced PPARγDNAbinding
activity while limited LPS-induced drop in PPARγ DNA binding
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FIGURE 5 | Pharmacological inhibition of PPARγ significantly prevented
UA-8 associated protective effects in LPS-induced cytotoxicity. NCMs
were treated with LPS (1μg/ml) and/or UA-8 (1 μm) in the presence of
GW 9662 (1 μm) for 24 h. (A) Pharmacological inhibition of PPARγ
prevented protective effect of UA-8 on cell viability. (B) Inhibition of
PPARγ abolished protective effect of UA-8 on ADP/ATP ratio in NCMS
exposed to LPS. (C) UA-8 did not reduce LPS-enhanced NF-kB DNA
binding activity in NCMs treated with the pharmacological inhibitor of
PPARγ. (D) Inhibition of PPARγ limited UA-8 inhibitory effect on caspase-3
activity in NCMs exposed to LPS. Values are represented as
mean ± SEM, N = 3–4. Signiﬁcance was set at P < 0.05. * Signiﬁcantly
different from control.
activity in NCMs (Figure 6D). Importantly, addition of 14,15-
EEZE abolished all protective effects of 14,15-EET similarly as
it was observed with UA-8. Thus, protective effects of UA-8 and
14,15-EET in LPS-induced cytotoxicity were biologically very sim-
ilar and sensitive to 14,15-EEZE suggesting they occurred through
an eicosanoid-speciﬁc signaling pathway(s).
DISCUSSION
In the present study, we provide evidence that EET-mediated
activation of PPARγ signaling is required to reduce LPS-induced
cytotoxicity in cardiomyocytes, demonstrating EETs may directly
regulate cardiac inﬂammatory responses.
Myocardial exposure to LPS can trigger low-grade inﬂamma-
tion reactions,which are initiated throughNF-κBsignaling leading
to release of cytokines such as TNFα and MCP-1 (Charalambous
et al., 2007). The subsequent stress and inﬂammatory response
triggers a cascade of events that may cause deleterious alterations
in mitochondrial function, leading to apoptotic cell death (Oddis
and Finkel, 1995; Ben-Shaul et al., 2001; Choumar et al., 2011). For
example, LPS treatment has been reported to induce depletion of
cardiac ATP, which was associated with myocardium dysfunction
(Drosatos et al., 2011). Consistent with the literature, our data
demonstrated that LPS induced a rapid loss of cell viability and
reduced mitochondrial oxidative metabolism. As expected, LPS
triggered a robust activation of the pro-inﬂammatory response in
cardiomyocytes as was seen with up-regulation of NF-kB DNA
binding activity and a dramatic reduction in PPARγ DNA binding
activity, which were followed by the release of TNFα and MCP-1.
The LPS-instigated execution of the pro-inﬂammatory response
was potentially the primary event causing activation of caspase-3
and collapse of the antioxidant capacity in NCMs.
In this study, we demonstrate that EETs stimulate a number
of adaptive responses enabling NCMs to withstand LPS-induced
cytotoxicity. Particularly, our data highlight that treatment with
EETs preserved cell viability, oxidative metabolic activity, dimin-
ished the pro-inﬂammatory response and reduced caspase-3
activity in cardiomyocytes exposed to LPS. The protective effects of
EETs were abolished by a co-treatment with its speciﬁc antagonist
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FIGURE 6 |Treatment with 14,15-epoxyeicosatrienoic acids (EET)
recapitulated protective effects of UA-8 in LPS-induced cytotoxicity.
NCMs were treated with LPS (1 μg/ml) and/or 14,15-EET (1 μm) in the
presence or absence of 14,15-EEZE (10 μm) for 24 h. (A) Treatment
with 14,15-EET signiﬁcantly improved LPS-decreased cell viability. (B,C)
14,15-EET signiﬁcantly attenuated LPS-triggered inﬂammatory response
as seen with reductions in NF-kB DNA binding activity and TNFα
release. (D) 14,15-EET induced an increase in PPARγ DNA binding
activity and signiﬁcantly prevented LPS-triggered drop in PPARγ DNA
binding activity. Values are represented as mean ± SEM, N = 3–4.
Signiﬁcance was set at P < 0.05. * Signiﬁcantly different from control.
# Signiﬁcantly different from LPS-treated cells.
14,15-EEZE providing evidence that the observed effects were
attributed to EETs speciﬁc pathways. There are two key results that
suggest the effects observed in the current study are attributed to
EETs: (1) the biological response was completely attenuated by the
EET-antagonist 14,15-EEZE; and, (2) we observe similar biologi-
cal effects with 14,15-EET and UA-8. Thus, we can conclude the
biological effects are mostly attributed to EET-mediated effects.
Although there is no EET speciﬁc receptor discovered yet,
numerous studies show the ability of EETs to act as cellular
signaling molecules regulating numerous pathways (Imig, 2012;
Shahabi et al., 2014). Evidence suggests that EETs may act through
a receptor(s) and demonstrate afﬁnity to known receptors (Wid-
strom et al., 2003; Spector and Norris, 2007). Currently, there is
limited information regarding the exact concentrations of EET
regioisomers found in cardiomyocytes but evidence indicates
bioavailability is inﬂuenced by various factors such as stress (Imig,
2012). Intriguingly, EETs may act as endogenous agonists to
PPARs, which increases VEGF and angiogenesis in endothelial
progenitor cells (Liu et al., 2005; Ng et al., 2007; Xu et al., 2013).
In contrast, LPS has been shown to cause a dramatic reduction
in the expression of PPARs (Feingold et al., 2004; Maitra et al.,
2009). Previously, we reported that treatment with LPS resulted
in a rapid decrease in PPARα DNA binding activity in NCMs and
PPARγ DNA binding activity in peritoneal macrophages. The pri-
mary observation from this study was that LPS-triggered a rapid
decline in PPARα and PPARγ DNA binding activities evoked
a robust pro-inﬂammatory response in both NCMs and peri-
toneal macrophages. Furthermore, restoring PPARα and PPARγ
DNA binding activities by inhibiting malonyl-CoA decarboxy-
lase signiﬁcantly limited LPS-triggered inﬂammatory response
(Samokhvalov et al., 2012). This may be a compelling obser-
vation validating the importance of ﬁnding novel agonists of
PPARs to develop new strategies targeting LPS-induced cytotoxic-
ity. Numerous reports postulate that activation of PPAR-signaling,
particularly PPARα and PPARγ, can suppress the inﬂammatory
response through inhibition of NF-kB pathways (Liu et al., 2005;
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FIGURE 7 | Schematic of proposed EET cardioprotective mechanism(s).
LPS triggers activation of NF-κB-dependent signaling and suppresses PPARγ
activation, resulting in a shift of the cellular response to a pro-inﬂammatory
state. Increased EETs can act as PPARγ agonists and inhibit NF-κ
B-dependent signaling, shifting the cellular response to an anti-inﬂammatory
state.
Wray and Bishop-Bailey, 2008). Nonetheless, the protective effects
of EETs are not limited to activating PPARγ-mediated signal-
ing pathways. There is strong evidence in the literature that
EETs suppress NF-kB-mediated induction and the subsequent
pro-inﬂammatory response through inhibition of IKK complex
activity (Deng et al., 2010), which partially occurs via activation of
PI3K-dependent Akt and EGF receptor signaling pathway (Zhao
et al., 2012). The involvement of PI3K signaling in EET-mediated
activation of PPARγ is possible mechanism of action. Our pre-
viously published studies suggest that EET triggered biologically
effects might involve PI3K (Batchu et al., 2011, 2012). Evidence
from the literature also suggests a complex interplay between PI3K
and PPARγ pathways (Chuang et al., 2007; Mishra et al., 2010).
Although these indirect pieces of evidence support the role of PI3K
cascade in EET-mediated events, further evidence is required to
understand the precise mechanism(s) of action. Considering evi-
dence showing desensitization to LPS is favorable in patients with
chronic heart failure (Charalambous et al., 2007), our current data
imply targeting PPARγ-mediated signaling with EETs would be a
possible novel therapeutic approach to treat LPS-induced cardiac
pathologies.
Enhanced release of pro-inﬂammatory cytokines from the
heart causes recruitment of mononuclear cells which has been
shown to have a role worsening the development of cardiovas-
cular disease (Zernecke et al., 2008). The therapeutic potential
for limiting inﬂammatory-induced migration of immune cells
in myocardium appears to be tremendous. Our ﬁndings illus-
trate for the ﬁrst time that EETs can effectively reduce LPS-
triggered release of the pro-inﬂammatory cytokines from NCMs.
While not deﬁnitive, we can still tentatively suggest that acting
as agonists to PPARγ, EETs can suppress LPS-induced pro-
inﬂammatory response thereby reducing cell death in NCMs.
Indeed, our observations indicate that activation of PPARγ sig-
naling contribute signiﬁcantly to EETs exerted protective effect.
This notion was supported when EET-associated protective effects
were abolished by pharmacological inhibition of PPARγ signaling.
In summary, we demonstrate a crucial role of PPARγ signaling
in mediating EET protective effects toward LPS-induced cyto-
toxicity in cardiomyocytes (Figure 7). While the precise cellular
and molecular mechanism(s) remain unknown, our data suggest
EETs exert their protective effect through activation of anti-
inﬂammatory
processes.
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